Bredicon 0.075 mg (Tablet)

Indications

• Contraceptive efficacy
• Prevent pregnancy
• Alternative for women with weak tolerance for estrogen
• Alternative for lactating or breast feeding women

Description

• Contains progestogen Bredicon
• Progestogen-only-pill (POP)
• Prevents sperm cells from entering womb
• May prevent egg cell from ripening
• Distinct from other mini-pills with high dose
• May cause irregular vaginal bleeding

Dosage & Administration

• Take one tablet at the same time each day
• Take continuously without a break
• Contains 28 tablets per strip
• Arrows and days printed for easy tracking
• Tablet should be taken within 3 hours of the same time each day
• Can be taken by women who do not tolerate estrogens
• Instructions for starting first pack, changing from combined pill, mini-pill, injection, implant, or hormonal IUD
• Guidelines for missed tablets and vomiting
• Storage instructions

Interaction

• Enzyme-inducing drugs may increase clearance and lead to breakthrough bleeding and contraceptive failure
• Reduced absorption with medical charcoal

Contraindications

• Known or suspected pregnancy
• Active venous thromboembolic disorder
• Severe hepatic disease with abnormal liver function tests
• Progestogen dependent tumors
• Undiagnosed vaginal bleeding
• Hypersensitivity to ingredients

Side Effects

• Common: irregular bleeding, amenorrhoea, headache, weight gain, breast pain, nausea, acne, mood changes, decreased libido
• Less common: Vaginitis, dysmenorrhoea, ovarian cysts, vomiting, alopecia, fatigue, difficulty wearing contact lenses
• Rare: Rash, urticaria, erythema nodosum

Pregnancy & Lactation

• Not recommended during pregnancy
• Does not affect the production or quality of breast milk
• Small amounts excreted in milk
• Long term follow-up data not available

Precautions & Warnings

• Increased incidence of venous thromboembolism with combined OCs
• Discontinue in the event of thrombosis
• Consider stopping prior to long term immobilization due to surgery or illness
• Benefit/risk assessment in women with liver cancer
• Caution for patients with a history of thromboembolic disorders
• Close monitoring for patients with diabetes
• Effects on bone density are unknown

Overdose Effects

• No serious deleterious effects reported from an overdose
• Symptoms may include nausea, vomiting, slight vaginal bleeding
• Treatment should be symptomatic

Therapeutic Class

• Oral Contraceptive preparations

Storage Conditions

• Store at room temperature (below 30°C)
• Do not use it after the expiry date stated on the package

Related Brands

• POP-D 0.075 mg (Tablet) - incepta-pharmaceuticals-ltd